Basf Se Corporation

Basf Aktiengesellschaft

Knoll Aktiengesellschaft

Basf Aktienegesellschaft

Basf Aktiengellsellschaft

Karl Kolter

Maximilian Angel

Axel Sanner

Michael Schönherr

Bernhard Fussnegger

Volker Schehlmann

Katrin Zeitz

Bernd Bruchmann

Ralf Pelzer

Helmut B Witteler

Walter Dobler

Gunther Berndl

Daniel Wagner

Kurt H Bauer

Rainer Dobrawa

Kristin Tiefensee

Monika Haberecht

Helmut Meffert

Hartwig Voβ

Ralf Widmaier

Reinhold Stadler

Herbert Bayer

Reiner Kober

Reinhold Saur

Ivette Garcia Castro

Ekkehard Jahns

Son Nguyen Kim

Hartwig Voss

Roland Ettl

Thomas Subkowski

Christof Wilhelm Wigbers

Frank Dietsche

Juergen Detering

Wolfgang Krause

Karl-Heinrich Schneider

Heike Weber

Jürgen Detering

J&ouml;rg Breitenbach

Siegfried Lang

Franz-Josef Dietzen

Silke Gebert

Angelika Maschke

Felicitas Guth

Hermann Ascherl

Kathrin Meyer-Böhm

Matthias Karl

Stefan Fischer

Michael Gotsche

Dejan Djuric

Folker Ruchatz

Kathrin Meyer-Boehm

Michael Kerber

Theo Smit

Loni Schweikert

Peter Schmidt

Bernhard Linner

Andreas Habich

Peter Schording

Wolf Pelletier

Frank Schmidt

Michael Klemens Müller

Christoph Hamers

Holger Türk

Sebastian Koltzenburg

Stefan Bruhns

Knut Oppenl&auml;nder

Michael Klemens Mueller

Frank Runge

Frank Rittig

Alfred Leinenbach

Marianna Pierobon

Michael Zirnstein

Marco Schmidt

Ingo Bellin

Rainer Blankenburg

Cedric Dieleman

Thomas Breiner

Claudia Esper

Karl-Hermann Strube

Michael Seufert

Roland Bodmeier

Jan Kurt Walter Sandler

Nathalie Bouillo

Helmut Fricke

Franz Weber

Ewelina Burakowska-Meise

Holger Ruckdäschel

Michael Sch&ouml;nherr

Torsten Knieriem

Christian Drohmann

Anisul Quadir

Simone Schillo

Erik Bohrer

Thrandur Helgason

Gabriele Lang-Wittkowski

Markus Steffen

Angelika Schmitt

Frank Fischer

Olga Pinneker

Volker Buehler

Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Terpolymers and their use in pharmaceutical dosage forms

An optically clear, solid water-soluble formulation of odorants and flavorings comprising at least one synthetically prepared odorant and flavoring, in which the odorants and flavorings are embedded homogeneously in a polymer matrix based on polyvinyllactams.

Solid solutions of odoriferous substances and flavoring agents with vinyl lactam polymers

The present invention relates to dust-free preparations dispersible in cold water. These preparations consist of particles comprising water-insoluble or only sparingly water-soluble active substance(s), said particles being coated with one or more layers, the outermost layer comprising as principal component one or more hydrophobic powdering agents on which at least one dispersant is absorbed. The invention also relates to a process for producing these particles and to the use thereof in food supplements, foodstuffs, animal feeds, personal-care products, and medicaments.

Dust-free cold-water-dispersible preparations

The use of powder-form, crosslinked, water-insoluble, low-swelling polyacrylates as disintegrants for solid pharmaceutical dosage forms.

Poly(meth)acrylic acid popcorn polymerizates as disintegrants for tablets

The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 &#x3bc;m and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to &#x2155; of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, wherein the wall material consists of a composition comprising at least one aliphatic-aromatic polyester, and the wall material has a solubility at 25&#xb0; C. of at least 50 g/l in dichloromethane, a method for the preparation thereof and also the use thereof.

Spherical microparticles with polyester walls

A finely divided binder in powder form consisting of a polyethylene glycol-polyvinyl alcohol graft polymer particles, wherein the particles have an average particle size D[4,3] in the range of from 10 to 70 &#x3bc;m.

Dry-binders for tablets based on polyethylene glycol-polyvinyl alcohol graft polymers, the production and use thereof

An odorant and flavoring formulation for topical application comprising, as matrix former, a mixture of at least one water-insoluble polymer from the group of homo- or co-polymers of C1-C4-carboxylic acid vinyl esters and at least one water-soluble polymer from the group of homo- or copolymers of N-vinyllactams.

Formulations with a controlled release of perfumes for dermal application

Pharmaceutical coatings obtained from coating compositions based on film-forming copolymers of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymers are present partially neutralized with C-C-dicarboxylic acids.

Production of pharmaceutical protective coatings with good resistance in a neutral environment

The present invention relates to a pulverulent vitamin formulation in which the vitamin essentially has a particle size of less than 0.7 &#x3bc;m and which comprises an effective amount of propyl gallate, and also to processes for producing this formulation, and to formulations obtainable by these processes and to the use thereof as animal feed, food, food supplement, personal care product or pharmaceutical composition. The formulations of the invention have improved stability compared to the prior art.

Propyl gallate-containing vitamin preparations

Described are solid dispersions of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of the monomers of from 35:65 to 55:45. Also described are the preparation and use of such solid dispersions for pharmaceutical dosage forms.

Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers

Water-soluble polymeric salts of medicaments sparingly soluble in water consisting of a cationogenic medicament which, in uncharged form or as hydrochloride, has a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice, and an anionogenic water-soluble polymer having a solubility in water of at least 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight.

Salts of active ingredients with polymeric counterions

Pharmaceutical formulation in the form of agglomerates comprising

Pharmaceutical formulation for the production of rapidly disintegrating tablets

Dosage forms comprising preparations of slightly water-soluble active substances in a polymer matrix of polyether copolymers, the polyether copolymers being obtained by free radical polymerization of a mixture of from 30 to 80% by weight of N-vinyllactam, from 10 to 50% by weight of vinyl acetate and from 10 to 50% by weight of a polyether, and of at least one slightly water-soluble polymer in which the slightly water-soluble active substance is present in amorphous form in the polymer matrix.

Solid pharmaceutical preparations containing copolymers based on polyethers combined with poorly water-soluble polymers

Dosage forms provided with protective coatings in which a core comprising at least one acidic active ingredient is provided with at least one inner and one outer coating layer, where the outer layer comprises, as component A, a cationic polymer which is an emulsion polymer of N,N-diethylaminoethyl methacrylate and further monomers.

Protective coatings for acidic active ingredients

A process for producing solid oral dosage forms with controlled active ingredient release, comprising a mixture of

Process for producing oral dosage forms with controlled release

Growing community of inventors

Limburgerhof, Germany

Karl Kolter